The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.

Abbiotec坚信与我们的科学家，客户，合作者和分销商社区建立牢固而有意义的合作伙伴关系。我们通过研究合作与社区分享我们的想法，并通过有益于生命科学界的创新和有用的产品来回馈青睐。我们欢迎有关研究或产品创意的讨论，我们将努力为此类讨论提供最有利和最机密的环境。Abbiotec利用专有技术和特殊资源开发自己的产品，以实现高质量的生产和控制。我们还从其他合作伙伴（例如个人科学家，大学外发许可部门和其他生物技术公司）获得产品和想法的许可。被许可的技术或想法被开发为商业产品，并通过我们的营销和销售网络在全球范围内销售。